Cargando…

Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease

Glycogen storage disease type Ia (GSD Ia) is caused by mutations in the glucose-6-phosphatase (G6Pase) catalytic subunit gene (G6PC). GSD Ia complications include hepatocellular adenomas (HCA) with a risk for hepatocellular carcinoma (HCC) formation. Genome editing with adeno-associated virus (AAV)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Hye-Ri, Gjorgjieva, Monika, Smith, Stephanie N., Brooks, Elizabeth D., Chen, Zelin, Burgess, Shawn M., Chandler, Randy J., Waskowicz, Lauren R., Grady, Kylie M., Li, Songtao, Mithieux, Gilles, Venditti, Charles P., Rajas, Fabienne, Koeberl, Dwight D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909089/ https://www.ncbi.nlm.nih.gov/pubmed/31890731 http://dx.doi.org/10.1016/j.omtm.2019.10.016

Ejemplares similares

Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia
por: Kang, Hye-Ri, et al.
Publicado: (2019)

Hepatic stress associated with pathologies characterized by disturbed glucose production
por: Gjorgjieva, Monika, et al.
Publicado: (2019)

Characterization of a canine model of glycogen storage disease type IIIa
por: Yi, Haiqing, et al.
Publicado: (2012)

Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases
por: Pursell, Natalie, et al.
Publicado: (2018)

Cellular and metabolic effects of renin-angiotensin system blockade on glycogen storage disease type I nephropathy
por: Monteillet, Laure, et al.
Publicado: (2021)

From Puppies to adults: In vivo editing of hepatocytes in a canine model of glycogen storage disease type Ia
por: Chandler, Randy J.
Publicado: (2023)

Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels
por: Saeed, Ali, et al.
Publicado: (2020)

Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context
por: Monteillet, Laure, et al.
Publicado: (2018)

Glucose-6 Phosphate, a Central Hub for Liver Carbohydrate Metabolism
por: Rajas, Fabienne, et al.
Publicado: (2019)

Increased atherosclerosis in a mouse model of glycogen storage disease type 1a
por: La Rose, Anouk M., et al.
Publicado: (2022)

Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa)
por: Farah, Benjamin L., et al.
Publicado: (2017)

Hydrostatic Isolated Limb Perfusion with Adeno-associated Virus Vectors Enhances Correction of Skeletal Muscle in Pompe Disease
por: Sun, Baodong, et al.
Publicado: (2010)

Impaired Very‐Low‐Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia
por: Hoogerland, Joanne A., et al.
Publicado: (2021)

Glucotoxicity Induces Glucose-6-Phosphatase Catalytic Unit Expression by Acting on the Interaction of HIF-1α With CREB-Binding Protein
por: Gautier-Stein, Amandine, et al.
Publicado: (2012)

Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a
por: Lei, Yu, et al.
Publicado: (2020)

Deficiency in MyD88 Signaling Results in Decreased Antibody Responses to an Adeno-Associated Virus Vector in Murine Pompe Disease
por: Zhang, Ping, et al.
Publicado: (2012)

Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia
por: Rutten, Martijn G. S., et al.
Publicado: (2023)

mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease
por: Cao, Jingsong, et al.
Publicado: (2021)

G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a
por: Roseman, Daniel S., et al.
Publicado: (2018)

The role of kidney in the inter-organ coordination of endogenous glucose production during fasting
por: Kaneko, Keizo, et al.
Publicado: (2018)

Corrigendum to “Assessment of toxicity and biodistribution of recombinant AAV8 vector–mediated immunomodulatory gene therapy in mice with Pompe disease”
por: Wang, Gensheng, et al.
Publicado: (2015)

Assessment of toxicity and biodistribution of recombinant AAV8 vector–mediated immunomodulatory gene therapy in mice with Pompe disease
por: Wang, Gensheng, et al.
Publicado: (2014)

Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control
por: Peeks, Fabian, et al.
Publicado: (2017)

The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice
por: Rajas, Fabienne, et al.
Publicado: (2020)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2017)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2019)

Glycogen Storage Disease Type Ia in Canines: A Model for Human Metabolic and Genetic Liver Disease
por: Specht, Andrew, et al.
Publicado: (2011)

Control of Blood Glucose in the Absence of Hepatic Glucose Production During Prolonged Fasting in Mice: Induction of Renal and Intestinal Gluconeogenesis by Glucagon
por: Mutel, Elodie, et al.
Publicado: (2011)

A caveolin-1 dependent glucose-6-phosphatase trafficking contributes to hepatic glucose production
por: Gautier-Stein, Amandine, et al.
Publicado: (2023)

Glycogen storage diseases: An update
por: Gümüş, Ersin, et al.
Publicado: (2023)

ON THE DIFFERING APPEARANCE OF INTRANUCLEAR AND CYTOPLASMIC GLYCOGEN IN LIVER CELLS IN GLYCOGEN STORAGE DISEASE
por: Sheldon, H., et al.
Publicado: (1962)

Next-generation glycogen storage diseases
por: Derks, Terry G. J., et al.
Publicado: (2018)

Biomarkers in Glycogen Storage Diseases: An Update
por: Molares-Vila, Alberto, et al.
Publicado: (2021)

Examination of the “susceptibility gap” in the treatment of canine heartworm infection
por: Bowman, Dwight D., et al.
Publicado: (2017)

Glycogen storage disease presenting as Cushing syndrome
por: Stefater, Margaret A., et al.
Publicado: (2019)

Neurological Characteristics of Pediatric Glycogen Storage Disease
por: Muzetti, Julio Henrique, et al.
Publicado: (2021)

Comparisons of Infant and Adult Mice Reveal Age Effects for Liver Depot Gene Therapy in Pompe Disease
por: Han, Sang-oh, et al.
Publicado: (2019)

An optimized method for tissue glycogen quantification
por: Schaubroeck, Kyle J., et al.
Publicado: (2022)

A Case of Glycogen Storage Disease IV with Rare Homozygous Mutations in the Glycogen Branching Enzyme Gene
por: Choi, So Yoon, et al.
Publicado: (2018)

Manipulating the Expression of Glycogen Phosphorylase in Synechococcus elongatus PCC 7942 to Mobilize Glycogen Storage for Sucrose Synthesis
por: Dan, Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_27sodnuns7tvmvlho296t86au0